Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced an upcoming presentation, entitled Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-Inflammation, showing data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation will be delivered at the European E-Congress of Rheumatology (EULAR) 2020. Additionally, preclinical data analyzing the role of the granulocyte macrophage colony stimulating factor (GM-CSF) pathway in giant cell arteritis (GCA) pathophysiology will be included in a poster presentation.\n Professor Lorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy will deliver an oral presentation of outcomes data from the mavrilimumab treatment protocol in COVID-19 pneumonia and hyperinflammation in Italy. Oral Presentation Details: Abstract #CO0001: Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-InflammationSession: EULAR COVID-19 RecommendationsDate and Time: Wednesday, June 3, 2020 from; 5:15pm to 5:25pm Central European Time (oral presentation); 4:30pm to 5:35pm Central European Time (full session)Lead Authors: Lorenzo Dagna, Giacomo De Luca1,2, Corrado Campochiaro1,2 There will also be a presentation of preclinical data analyzing the role of the GM-CSF pathway in GCA pathophysiology delivered by Dr. Maria C. Cid, MD, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Vasculitis Research Unit, Department of Autoimmune Diseases, Barcelona, Spain. Poster Presentation Details: Abstract #FRI0010: GM-CSFR Pathway is Implicated in Pathogenic Inflammatory Mechanisms in Giant Cell ArteritisSession: A Journey into the Innate Immune Mechanisms Driving Rheumatic Diseases and Novel Therapeutic StrategiesDate and Time: Friday, Ju...

More updates from Kiniksa Pharmaceuticals International, Plc